Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 4
2011 3
2012 5
2013 2
2014 5
2015 1
2016 3
2017 6
2018 20
2019 13
2020 10
2021 13
2022 15
2023 13
2024 8
2025 16
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol. ...In the febuxostat gr …
Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-lice …
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibit …
BACKGROUND: Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with feb …
Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis.
Guan X, Zhang S, Liu J, Wu F, Zhou L, Liu Y, Su N. Guan X, et al. Front Pharmacol. 2022 Sep 30;13:998441. doi: 10.3389/fphar.2022.998441. eCollection 2022. Front Pharmacol. 2022. PMID: 36249825 Free PMC article.
Background: Gout is a common disease and is usually treated with uric acid-lowering drugs (the most commonly used of which are febuxostat and allopurinol). However, the cardiovascular safety of febuxostat and allopurinol is still controversial. ...Rand …
Background: Gout is a common disease and is usually treated with uric acid-lowering drugs (the most commonly used of which are febuxostat …
Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials.
Ghossan R, Aitisha Tabesh O, Fayad F, Richette P, Bardin T. Ghossan R, et al. J Clin Rheumatol. 2024 Mar 1;30(2):e46-e53. doi: 10.1097/RHU.0000000000002045. Epub 2023 Dec 20. J Clin Rheumatol. 2024. PMID: 38115182
We aimed to compare the cardiovascular outcomes in the most pertinent trials of febuxostat compared with controls. ...Overall, the data of cardiovascular safety of febuxostat were reassuring. CONCLUSIONS: Our systematic review showed high level …
We aimed to compare the cardiovascular outcomes in the most pertinent trials of febuxostat compared with controls. ...Overall, …
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Gao L, Wang B, Pan Y, Lu Y, Cheng R. Gao L, et al. Clin Cardiol. 2021 Jul;44(7):907-916. doi: 10.1002/clc.23643. Epub 2021 May 20. Clin Cardiol. 2021. PMID: 34013998 Free PMC article.
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This meta-analysis adds new evidence regarding the cardiovascular safety of febuxostat in patients. Initiation of febuxosta …
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This me …
Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis.
Zhang S, Xu T, Shi Q, Li S, Wang L, An Z, Su N. Zhang S, et al. Front Med (Lausanne). 2021 Jun 15;8:698437. doi: 10.3389/fmed.2021.698437. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34211992 Free PMC article.
Background: Hyperuricemia is a common metabolic disease and has become a public health problem because of its increasing prevalence and association with comorbidities. Allopurinol and febuxostat are recommended as the first-line treatments for hyperuricemia and gout. But …
Background: Hyperuricemia is a common metabolic disease and has become a public health problem because of its increasing prevalence and asso …
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis.
Deng JH, Lai PH, Xie LS, Qiu SS, Qiu DS, Zhang JX. Deng JH, et al. Clin Transl Sci. 2024 Mar;17(3):e13757. doi: 10.1111/cts.13757. Clin Transl Sci. 2024. PMID: 38488426 Free PMC article.
The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian patients is uncertain. In this study, we conducted a systematic review and meta-analysis to compare the CV safety profiles of febuxos …
The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian pat …
Cardiovascular safety of febuxostat.
Xu C. Xu C. Lancet. 2021 Sep 11;398(10304):954-955. doi: 10.1016/S0140-6736(21)01385-4. Lancet. 2021. PMID: 34509227 No abstract available.
Cardiovascular safety of febuxostat.
Singh JA. Singh JA. Lancet. 2021 Sep 11;398(10304):955. doi: 10.1016/S0140-6736(21)01386-6. Lancet. 2021. PMID: 34509229 No abstract available.
Cardiovascular safety of febuxostat - Authors' reply.
MacDonald TM, Nuki G, Robertson M, Ford I, Mackenzie IS. MacDonald TM, et al. Lancet. 2021 Sep 11;398(10304):955-956. doi: 10.1016/S0140-6736(21)01383-0. Lancet. 2021. PMID: 34509228 No abstract available.
130 results